Our
News
Check back on a regualr basis
for futher updates.
First patient enrolled in NG11-2 Phase Ib clinical trial
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer.
VasoDynamics Receives Global Health & Pharma Biotechnology 2023 Award
VasoDynamics Receives Global Health & Pharma Biotechnology 2023 Award VasoDynamics receives Global Heath & Pharma Biotechnology Award 2023 as Most Patient-Centric Cancer Care Solutions Provider -
VasoDynamics Receives UK MHRA-REC Approval On NG11-2 Phase Ib Clinical Trial
VasoDynamics Receives UK MHRA-REC Approval On NG11-2 Phase Ib Clinical Trial A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral
VasoDynamics files UK patent for Radiotherapy-Induced Oral Mucositis (RIOM) Clinical Trial Methodology
VasoDynamics files UK patent for Radiotherapy-Induced Oral Mucositis (RIOM) Clinical Trial Methodology Establishes Intellectual Property protection for proprietary RIOM clinical trial design 22nd December 2022 -
VasoDynamics submits UK Clinical Trial Application for NG11-2
VasoDynamics submits UK Clinical Trial Application for NG11-2 A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in
VasoDynamics establishes Clinical and Scientific Advisory Board
VasoDynamics establishes Clinical and Scientific Advisory Board Leading cancer research and treatment experts join our journey to tackle the debilitating side effects of cancer therapies 30th
